Skip to main content
. 2018 May 20;16(6):1121–1127. doi: 10.1111/jth.14129

Figure 2.

Figure 2

Cumulative incidence of venous thromboembolism accounting for competing mortality according to the IDH1 status and podoplanin expression in primary brain tumor patients. To predict the risk of brain cancer‐associated VTE, a score was established based on the sum of the IDH1 status (mut = 0, wt = 1) and podoplanin expression levels (no = 0, low = 1, medium = 2, high = 3). Brain tumor patients with the combination of IDH1wt and high podoplanin expression were at highest risk of VTE, whereas patients with IDH1 R132H mutation combined with no podoplanin expression showed the lowest risk of developing VTE during the follow‐up time. As IDH1 mutation and podoplanin overexpression (medium, high) appear to be exclusive, only the score of 1 included a heterogenous subgroup of tumors. All other scores (0, 2–4) included homogenous subgroups regarding IDH1 status and podoplanin expression levels: score 0 = IDH1mut with no podoplanin; score 1 = IDH1mut with low podoplanin and IDH1wt with no podoplanin; score 2 = IDH1wt with low podoplanin; score 3 = IDH1wt with medium podoplanin; score 4 = IDH1wt with high podoplanin (mut, mutant; wt, wild‐type). [Colour figure can be viewed at http://wileyonlinelibrary.com]